Paul Berns - Jazz Pharmaceuticals Independent Director

JAZZ -- USA Stock  

USD 128.66  0.41  0.00%

Mr. Paul L. Berns is an Independent Director of Jazz Pharmaceuticals PLC. Mr. Berns has served as a member of our board of directors since the closing of the Azur Merger in January 2012 and was a director of Jazz Pharmaceuticals, Inc. from 2010 until the closing of the Azur Merger. Mr. Berns is a consultant to the pharmaceutical industry. From March 2014 to June 2016, he served as the Chief Executive Officer and President of Anacor Pharmaceuticals, Inc., a biopharmaceutical company, which was acquired by Pfizer Inc. in June 2016. He also served as a member of the board of directors of Anacor Pharmaceuticals, Inc. from 2012 until 2016, including as Chairman of its board of directors from 2013 until 2016. From September 2012 to March 2014, he was a selfemployed consultant to the pharmaceutical industry. From March 2006 to September 2012, he served as President and Chief Executive Officer, and as a member of the board of directors, of Allos Therapeutics, Inc., a pharmaceutical company acquired by Spectrum Pharmaceuticals, Inc. From July 2005 to March 2006, Mr. Berns was a selfemployed consultant to the pharmaceutical industry. From June 2002 to July 2005, Mr. Berns was President, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporationrationration in 2005. From 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories, a pharmaceutical company. From 2000 to 2001, Mr.served as Vice President, Marketing of BASF PharmaceuticalsKnoll, a pharmaceutical company, and from 1990 to 2000, Mr. Berns held various positions, including senior management roles, at BristolMyers Squibb Company, a pharmaceutical company
Age: 50  Director Since 2010      
353 1 634 7800
Berns received a B.S. in Economics from the University of Wisconsin. With his experience as Chief Executive Officer of Allos Therapeutics, Inc., Anacor Pharmaceuticals, Inc. and Bone Care International Inc., and his experience serving

Paul Berns Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.1 % which means that it generated profit of $8.1 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 18.92 % meaning that it created $18.92 on every $100 dollars invested by stockholders.
The company currently holds 1.59B in liabilities with Debt to Equity (D/E) ratio of 52.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Jazz Pharmaceuticals has Current Ratio of 4.2 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Mark ChenChina Cord Blood Corporation
Stephen HoffmanDicerna Pharmaceuticals
Napoleone FerraraDelMar Pharmaceuticals
Natale RicciardiDynavax Technologies Corporatio
Roger JeffsDova Pharmaceuticals
John BellDelMar Pharmaceuticals
Daniel KisnerDynavax Technologies Corporatio
Peter KolchinskyDicerna Pharmaceuticals
Steven GoldmanDova Pharmaceuticals
Martha DemskiEquillium
Calvin RobertsAuris Medical Holding AG
Mats BlomAuris Medical Holding AG
Albert ChenChina Cord Blood Corporation
Frederick DriscollNantKwest
Antoine PapiernikAuris Medical Holding AG
Nancy WysenskiDova Pharmaceuticals
Vicki SatoDenali Therapeutics
John PottsNantKwest
Berndt ModigAuris Medical Holding AG
John FisherEquillium
Jay FlatleyDenali Therapeutics

Entity Summary

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. In addition, it evaluates deuterated oxybate for narcolepsy and sells psychiatry and other products. Jazz Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 1290 people.Jazz Pharmaceuticals Public Limited Company (JAZZ) is traded on BATS Exchange in USA. It is located in Waterloo Exchange and employs 1,290 people. Jazz Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Jazz Pharmaceuticals Leadership Team

Matthew Young, CFO and Executive VP
Paul Berns, Independent Director
Iain McGill, Senior Vice President - Jazz Pharmaceuticals Europe and Rest of World
Daniel Swisher, President COO
Suzanne Hooper, Executive VP and General Counsel
Rick Winningham, Independent Director
Peter Gray, Independent Director
Heather McSharry, Independent Director
Michael Miller, Sr. VP of U.S. Commercial
Katherine Littrell, Vice President - Investor Relations
Paul Treacy, Senior Vice President Technical Operations
Patrick Enright, Independent Director
Karen Wilson, Senior Vice President - Finance, Principal Accounting Officer
Norbert Riedel, Independent Director
Seamus Mulligan, Director
Russell Cox, COO and Executive VP
Catherine Sohn, Independent Director
Karen Smith, Global Head of Research & Development and Chief Medical Officer
Elmar Schnee, Independent Director
Kenneth OKeefe, Independent Director
Bruce Cozadd, Co-Founder, Executive Chairman and CEO

Stock Performance Indicators

Current Sentiment - JAZZ

Jazz Pharmaceuticals Investor Sentiment

Most of Macroaxis users are currently bullish on Jazz Pharmaceuticals Public Limited Company. What is your judgment towards investing in Jazz Pharmaceuticals Public Limited Company? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of macroaxis ideas.